Fadi Haddad, MD
UT MD Anderson · M.D. Anderson Cancer Center · Sharp HealthCare
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fadi Haddad, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:44 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07604233 · Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLM.D. Anderson Cancer Center · not yet recruiting · Myeloid Leukemia · principal investigator
- Ph2NCT07269470 · Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center · recruiting · Chronic Myeloid Leukemia · principal investigator
- Ph2NCT06817720 · Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or AsciminibM.D. Anderson Cancer Center · recruiting · Chronic Myeloid Leukemia · principal investigator
- N/ANCT04402814 · IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.Fadi Haddad, M.D. · unknown · SARS-CoV 2 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:44 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.